Amanda B. McFarland, Senior Consultant, Valsource, LLC
Amanda Bishop McFarland, M.S. is a Quality Risk Management and Microbiology Consultant with Valsource, LLC with over 15 years industry experience. She specializes in the creation and implementation of Risk Management programs and in developing risk-based strategies for use in Microbiology. She has a Bachelors of Science (Entomology) and a Masters of Science in Mycology both from the University of Florida. Amanda is an active member of the Parenteral Drug Association (PDA); a faculty member of the PDA’s Quality Risk Management training series and the Quality Risk Management Interest Group co-lead.
Emma Ramnarine, Senior Director, Head, Global Analytical Science & Technology, Genentech/Roche
Emma Ramnarine is accountable for the strategic direction and leadership for analytical methods, technologies, and control systems for Roche’s commercial Biologics and Small Molecule products — includes establishing and maintaining up-to-date, compliant and harmonized analytical control systems, proactive lifecycle management, technology innovation, method transfers, stability program, raw materials and reference standards management.
Emma has over 17 years of experience in the pharmaceutical, biotechnology and medical device industry in Quality System Management including developing and leading Quality Risk Management (QRM) programs. She is a worldwide-recognized expert on QRM, providing QRM leadership, governance, guidance, and training to regulatory authorities and at industry forums. She led the Task Forces for PCMOSM Technical Report Series No. 54 on “Implementation of Quality Risk Management”. She also led PDA’s Task Force for Technical Report No. 68 on “Risk Based Approach for Prevention and Management of Drug Shortages”, and is a representative for PDA on the inter-association European Drug Shortages Team that was formed under EMA’s direction.
Emma currently co-leads PDA’s Post Approval Change Task Force; she is on the PDA Board of Directors, PDA’s Regulatory Affairs and Quality Advisory Board (RAQAB), leads PDA’s QRM Interest Group, and has led the development of several PDA Technical Reports.
H. Gregg Claycamp, PhD, Senior Biomedical Research Scientist, Risk Analysis and Decision Analysis, U.S. FDA
Dr. Claycamp is a Senior Biomedical Research Service (SBRS) appointee whose duties include Risk Analysis and Decision Analysis in the Office of New Animal Drugs (CVM). He joined the FDA in 2001 to work on human health risk assessment from drugs approved for use in food animals in addition to a variety of risk analysis and decision analysis for regulatory scientific review and compliance problems. Since 2001 he also served as Director of the Div. of Compliance Risk Management and Surveillance in the Center for Drug Evaluation and Research (CDER) Office of Compliance. Dr. Claycamp continues to work on a portfolio of risk problems, risk management systems, and decision analysis tools for various levels of drug review and post-marketing risk management. He frequently speaks at industry and scientific conferences and publishes on these topics; reviews for a variety of risk and regulatory science journals; and teaches FDA courses in Risk Analysis and Risk-Informed Decision Making. Dr. Claycamp also serves on international working groups who developed “quality risk management” as a systems-based approach integrating quality systems and risk management for drug manufacturing. He was the regulatory lead for the final, internationally-harmonized guideline, "ICH Q9: Quality Risk Management” (http://www.ich.org). Presently, he is part of the design and delivery of risk management training for the PIC/S organization, which now include ~50 regulatory agencies worldwide. Dr. Claycamp’s AB is in Human Biology from Stanford University; MS and PhD degrees are in Radiological Health Engineering from Northwestern University. Prior to joining FDA, Dr. Claycamp was a Professor at the University of Pittsburgh where he directed graduate training programs in Risk Assessment and Radiation Health while maintaining an active research career including 70+ publications. He previously served on faculties of Radiation Biophysics at the Univ. of Kansas and the Dept. of Radiology at the Univ. of Iowa.